TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00705484
Drug: Standard Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: The standard therapy group will consist of participants receiving a treatment regimen that does not include Remicade. The treatment of each standard therapy participant will be left to the discretion of the treating physician and may change during the course of a participant's participation in the registry.
Study: NCT03759678
Drug: IB1001
Approvals — FDA: no, EMA: no, PMDA: no
Description: IB1001 (N-Acetyl-L-Leucine) is a modified amino-acid ester that is orally administered.
Study: NCT02621060
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: 1200 mg per day for three months
Study: NCT00567177
Drug: Restasis, Refresh Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restasis 0.4ml- (in the eye) Instill one drop twice daily in morning and evening Refresh Plus 0.4ml- (in the eye) Instill one drop twice daily in morning and evening
Study: NCT03092206
Drug: E/C/F/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: antiretroviral therapy
Study: NCT03769285
Drug: Nicotinamide
Normalized name: Nicotinamide
DrugBank: Nicotinamide (DB02701)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral nicotinamide (500 mg) twice daily for at least 52 weeks
Study: NCT03769285
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo taken twice daily for at least 52 weeks
Study: NCT04329403
Drug: Differin 0.1% Topical Gel
Normalized name: Differin 0.1% Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: A thin film of the assigned medication to be applied once daily in the evening for 12 weeks
Study: NCT00766090
Drug: GW685698X
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Corticosteroid
Study: NCT03556436
Drug: YH25448 240mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: period 1: A single oral dose of YH25448 240 mg an overnight fast period 2: A single oral dose of YH25448 240 mg after a high-fat breakfast
Study: NCT01750931
Drug: Meloxicam GSK 15mg
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: To demonstrate the bioequivalence of Meloxicam 15 mg tablets manufactured by Savipharm J.S.C, Vietnam and Mobic® 15 mg tablets of Boehringer Ingelheim Pharma GmbH \&amp; Co.KG Binger Str.173, 5521 Ingelheim am Rhein, Germany, in healthy adult human male subjects under fed condition
Study: NCT02207998
Drug: Placebo and physiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unmedicated lactose tablets. Physiotherapy: lower back classic massage, lumber joint manipulation and the application of a hot pack
Study: NCT02132884
Drug: targeted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receive specific targeted therapy
Study: NCT00244387
Drug: SPM 962
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02981264
Drug: Transcricoid Injection
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02086188
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill manufactured to mimic Mirabegron 25mg tablet.
Study: NCT02981264
Drug: Spray as you go
Normalized name: Go-dry
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00234078
Drug: 0.5% OPC-12759
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00234078
Drug: 1% OPC-12759
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00234078
Drug: 2% OPC-12759
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00234078
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00139178
Drug: Different HAART regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02290626
Drug: Semi-solid diet
Normalized name: Corydalis solida whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semi-solid diet is administered using PEG.
Study: NCT01536951
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT03471078
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator tablet
Study: NCT00397033
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 6 weeks
Study: NCT02248597
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00078325
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets once daily in the morning
Study: NCT04587778
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous infusion
Study: NCT03054922
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion of 0.9% NaCl throughout surgery.
Study: NCT03054922
Drug: Normosol-R Inj
Normalized name: NORMOSOL-R INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion of Normosol throughout surgery.
Study: NCT04587778
Drug: Pilot study II: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous infusion
Study: NCT01269801
Drug: JUVÉDERM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 will initially receive BOTOX® Cosmetic or VISTABEL® injections to the affected facial regions;~• Group 2 will initially receive JUVÉDERM® Ultra XC or JUVÉDERM® Ultra 2 (for moderate facial lines or folds) or JUVÉDERM® Ultra Plus XC or JUVÉDERM® Ultra 3 (for severe facial lines or folds) injections to the affected facial regions.~At 4 weeks,Group 1 patients who initially received BOTOX® Cosmetic or VISTABEL® treatment will be crossed over and receive JUVÉDERM® treatment, and Group 2 patients who initially received JUVÉDERM® treatment will be crossed over to receive BOTOX® Cosmetic or VISTABEL® treatment.
Study: NCT00710736
Drug: ARRY-334543, EGFR/ErbB2 inhibitor; oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple dose, escalating
Study: NCT00710736
Drug: Capecitabine, 5-fluorouracil prodrug; oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple dose, single schedule
Study: NCT03632590
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo capsules will contain starch (Amylum solani) for 24 weeks
Study: NCT03805750
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched Placebo
Study: NCT00236769
Drug: norelgestromin + ethinyl estradiol
Normalized name: ethinyl estradiol / norelgestromin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00924105
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: s.c. injection
Study: NCT02341638
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00756080
Drug: citrulline
Normalized name: Citrulline
DrugBank: Citrulline (DB00155)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.06 G/kg three times/day during 7 days
Study: NCT01124929
Drug: RNTCP Category I treatment for 6 months
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2H3R3Z3 E3 + 4H3R3
Study: NCT01124929
Drug: RNTCP Category I treatment for 9months
Normalized name: Retinoids for cancer treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2H3R3Z3 E3 + 7H3R3
Study: NCT01552291
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30g oral maltodextrin / day for 5 days before surgery
Study: NCT02447055
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02453490
Drug: 5-fluorouracil-based chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracil:400mg/m2,ivp,2h,d1,1200mg/m2/d\*2d(2400mg/m2,iv46-48h); Oxaliplatin:85mg/m2 iv,d1,q2w
Study: NCT04310085
Drug: Artemether-Lumefantrine 20 Mg-120 Mg Oral Tablet
Normalized name: artemether-lumefantrine 20 mg-120 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: artemether-lumefantrine 6 x of 4 tablets at approximately 0, 8, 24, 36, 48 and 60 h
Study: NCT00524862
Drug: Optimized medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta Blockers, ACE inhibitor or ARB, loop diuretics and/or spironolactone as appropriate, statin if indicated, aspirin and/or warfarin if indicated
Study: NCT00068575
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 175 mg/m\^2/day continuous infusion over 6 1/2 weeks for total 3 courses: Days 1-19 and 29-45, Days 71-108 and Days 127-168.
Study: NCT00890981
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to denosumab subcutaneously every 6 months in the previous study
Study: NCT00868985
Drug: PEG 3350 plus electrolytes
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each patient was treated with PEG 3350 with electrolytes for 10 days at a dose of either one, two or three sachets per day.
Study: NCT00868985
Drug: PEG 3350 without electrolytes
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each patient was treated with PEG 3350 for 10 days at a dose of either one, two or three sachets per day.
Study: NCT00868010
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a placebo pill for 12 weeks if randomized to this treatment.
Study: NCT05172622
Drug: JP-2266
Normalized name: ALCOHOL 70 mL in 100 mL TOPICAL GEL [JP P Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Single Ascending Dose: Single administration on Day 1~* Food effect cohort: Single administration on Day 1 of each period~* Multiple Ascending Dose: Repeated administrations from D1 to D15
Study: NCT05172622
Drug: JP-2266 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Single Ascending Dose: Single administration on Day 1~* Food effect cohort: Single administration on Day 1 of each period~* Multiple Ascending Dose: Repeated administrations from D1 to D15
Study: NCT00626249
Drug: Technosphere Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Technosphere Inhalation Powder
Study: NCT02852655
Drug: MK-3475
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01651715
Drug: TAO1, oral homeopathic antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAO1 comprises a mixture of homeopathic dilutions C12+C30+C200 (drug product is made by impregnation of pre-made tablets).~The investigational product will be taken for 7 days as follow:~Day 1: 3 tablets over the first 2 hours of treatment, then 3 tablets over the rest of Day 1.~Days 2-3: 5 tablets/day (intakes distributed evenly over the daytime). Days 4-7: 3 tablets/day (intakes distributed evenly over the daytime).
Study: NCT00545597
Drug: Lorenzo's oil
Normalized name: LORENZO'S OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4:1 glyceryl trioleate-glyceryl trierucate (Lorenzo's oil)given orally, daily as approximately 10% of nutritional calories with supplementation.
Study: NCT02670070
Drug: gemigliptin 50mg, rosuvastatin 20mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemigliptin/rosuvastatin 50/20mg
Study: NCT00130195
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00130195
Drug: prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00153803
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events death or completion of 3 years of therapy.
Study: NCT00130195
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00862979
Drug: Enteric coated mycophenolate sodium (EC-MPS)
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 180 mg or 360 mg tablet dosed 1440-2280 mg per day
Study: NCT00862979
Drug: Corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: according to local standard: 0.05-0.3 mg/kg of prednisolone or equivalent
Study: NCT00384852
Drug: rhBMP-2/CPM
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01533298
Drug: CombiflexOmega peri
Normalized name: casanthranol / docusate sodium Oral Capsule [Peri-Colace]
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenously over 3 days infusion
Study: NCT00507949
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: sachets of granulate of 160 mg. Dosage 160 mg b.i.d. Duration 8 weeks.
Study: NCT03208764
Drug: Nitric Oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will be treated with 91 thirty minute sessions of 160 ppm Nitric Oxide with at least 3 hours between each session.
Study: NCT01143727
Drug: Tegaderm Hydrogel
Normalized name: Tegaderm Hydrogel Wound Filler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply once 24-hr period sufficient to cover the wound.
Study: NCT03588988
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who underwent spine, hip or femur surgery and who were admitted to the ICU after institutional exhalation were randomly assigned to the DEX group and the control group. Both groups can be combined with remifentanil for appropriate postoperative analgesia. The control group is inoculated with saline solution. At this time, the patient's blood pressure, oxygen saturation and cardiopulmonary function are continuously monitored.
Study: NCT00503594
Drug: Methotrexate and temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate and temozolomide
Study: NCT00503594
Drug: Methotrexate , procarbazine ,vincristine ,cytarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate , procarbazine ,vincristine ,cytarabine
Study: NCT04641455
Drug: Espumisan, N acetylcystein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of mucolytic solution before upper endoscopy (Espumisan 320 mg, ACC long 600 mg)
Study: NCT04641455
Drug: Espumisan, N acetylcystein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of mucolytic solution before upper endoscopy (Espumisan 20 mg, ACC long 200 mg)
Study: NCT02108860
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Those randomized to placebo will receive a sterile placebo solution administered by subcutaneous injection once a week.
Study: NCT02047539
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00587470
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01167725
Drug: FOLFIRI regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT01167725
Drug: FOLFOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT01167725
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01167725
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01167725
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00397241
Drug: placebo (artificial tears)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03292653
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Tablet; Route of administration: Oral
Study: NCT02278887
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The patient receives 2 days cyclophosphamide via IV to deplete T-cells.
Study: NCT01046942
Drug: Clopidogrel+acetylsalicylic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: loading dose clopidogrel 300mg on second postoperative day. Thereafter 75mg clopidogrel daily for 3 months Aspirin 75mg daily, started within 24 hours after surgery
Study: NCT01046942
Drug: acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: aspirin 75 mg daily, started 6-24 hours after surgery
Study: NCT03798626
Drug: Modified FOLFOX6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin \[5 mg/mL concentration; administered IV\], leucovorin \[10 mg/mL concentration; administered IV\] (or levoleucovorin \[10 mg/mL concentration; administered IV\]), and 5-fluorouracil \[50 mg/mL concentration; administered IV\]
Study: NCT03798626
Drug: FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan \[20 mg/mL concentration; administered IV\], leucovorin \[10 mg/mL concentration; administered IV\] (or levoleucovorin \[10 mg/mL concentration; administered IV\]), and 5-fluorouracil \[50 mg/mL concentration; administered IV\]
Study: NCT01866163
Drug: LEO 90100
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01866163
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00206583
Drug: EV/DNG (Qlaira, BAY86-5027, SH T00658ID)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GA: Estradiolvalerate (EV)/Dienogest (DNG) Tablet p.o. (oral) Tablet, p.o. (oral)
Study: NCT01194453
Drug: cisplatin, dexamethasone,vitamin B12, folic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients received cisplatin 75mg/m2 plus pemetrexed 500 mg/m2 on day 1.Chemotherapy was repeated every 3 weeks for a maximum of six cycles.Patients received dexamethasone prophylaxis of 3.75mg orally twice per day on the day before, the day of, and the day after each day-1 treatment. patients received oral folic acid (1,000ug)daily and a vitamin B12 injection (1,000 ug) every 9 weeks, beginning 1 to 2 weeks before the first dose and continuing until 3 weeks after the last dose of study treatment
Study: NCT00228397
Drug: CCI-779
Normalized name: dengue virus live antigen, CYD serotype 1
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02894710
Drug: Glucose 5% (placebo)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in control group received an intravenous bolus injection of 0,075mL/kg of placebo (Glucose 5%) by a continuous lidocaine infusion of 0,1mL/kg/hr of placebo (Glucose 5%) during surgery and 0,05mL/kg/hr of placebo (Glucose 5%) in recovery room.
Study: NCT02146261
Drug: E6011
Normalized name: LARYNGEAL PROSTHESIS,BLOM-SINGER BE6011
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration of E6011 (at doses of 50, 100, 200 and 400 mg)
Study: NCT02146261
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration of placebo
Study: NCT02008279
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC injections of placebo (number of injections to equal number of injections of CNTO 3157)
Study: NCT00525044
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00959036
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo every 4 weeks
Study: NCT00959036
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01524198
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 ml to 1.5 ml normal saline (to complete 3 mls total volume), plus albuterol plus ipratropium bromide nebulizations 3 doses back to back
Study: NCT01183585
Drug: RO4917838 and Rosuvastatin
Normalized name: rosuvastatin and ezetimibe
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: multiple oral doses of RO4917838 and single oral dose of Rosuvastatin
Study: NCT01529177
Drug: Clomiphene citrate / hCG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomiphene citrate 50 mg daily for one month, then twice daily for 2 months then 3 times per day for 3 months.
Study: NCT00668070
Drug: ASP9831
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT00668070
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT02466867
Drug: Naftin® Cream, 2% (younger pediatric cohort)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Approximately 3 grams of Naftin® Cream, 2% ist to be applied once per day for subjects aged 2 to 5 years, 11 months.
Study: NCT02466867
Drug: Naftin® Cream, 2% (older pediatric cohort)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Approximately 4 grams of Naftin® Cream, 2% ist to be applied once per day for subjects aged 6 to 11 years, 11 months.
Study: NCT01998620
Drug: Ademetionine 2
Normalized name: ADEMETIONINE
DrugBank: Ademetionine (DB00118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ademetionine 1000mg ivgtt qd with general antiviral treatment for 2 weeks, then Ademetionine 500mg po bid with general antiviral treatment for 8 weeks
Study: NCT01998620
Drug: Ademetionine 1
Normalized name: ADEMETIONINE
DrugBank: Ademetionine (DB00118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ademetionine 2000mg ivgtt qd with general antiviral treatment for 2 weeks, then Ademetionine 1000mg bid po with general antiviral treatment for 8 weeks
Study: NCT01998620
Drug: Ademetionine 3
Normalized name: ADEMETIONINE
DrugBank: Ademetionine (DB00118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: no treatment for 2 weeks, then Ademetionine 1000mg bid po with general antiviral treatment for 8 weeks
Study: NCT00404820
Drug: Zoledronic acid 5 mg solution
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid was supplied as a concentrate of 5.33 mg zoledronic acid monohydrate in a 100 ml solution. 5.33 mg zoledronic acid monohydrate equals 5 mg zoledronic acid.
Study: NCT00404820
Drug: Calcium/Vitamin D
Normalized name: CALCIUM/VITAMIN D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined elemental calcium / vitamin D chewable tablets. Participants took 2 tablets a day, for a daily dose of calcium 1200 mg/vitamin D 800 IU.
Study: NCT04489264
Drug: Transplant, Autologous
Approvals — FDA: no, EMA: no, PMDA: no
Description: high dose chemotherapy followed by autologous stem cell transplantation
Study: NCT02456597
Drug: lidocainhydrochlorid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine injected through the novel Catheter
Study: NCT02456597
Drug: Isotonic Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline injected through the novel Catheter
Study: NCT00382239
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection twice daily, 0.02 mL to 0.04 mL
Study: NCT03581422
Drug: hCG administration before embryo transfer
Normalized name: human embryo tissue preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thawed embryo transfer with ovulation triggered by hCG